S&P 500   3,974.66 (+1.88%)
DOW   31,905.05 (+2.06%)
QQQ   292.50 (+1.32%)
AAPL   142.57 (+3.62%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,228.67 (+2.32%)
AMZN   2,145.31 (-0.30%)
TSLA   673.31 (+1.42%)
NVDA   167.74 (+0.48%)
BABA   86.51 (-0.32%)
NIO   15.78 (-4.01%)
AMD   94.68 (+1.26%)
CGC   5.18 (-6.16%)
MU   69.33 (+0.62%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.11 (+2.63%)
AMC   11.67 (-2.99%)
PFE   53.11 (+1.22%)
PYPL   81.04 (+0.62%)
NFLX   185.30 (-0.56%)
S&P 500   3,974.66 (+1.88%)
DOW   31,905.05 (+2.06%)
QQQ   292.50 (+1.32%)
AAPL   142.57 (+3.62%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,228.67 (+2.32%)
AMZN   2,145.31 (-0.30%)
TSLA   673.31 (+1.42%)
NVDA   167.74 (+0.48%)
BABA   86.51 (-0.32%)
NIO   15.78 (-4.01%)
AMD   94.68 (+1.26%)
CGC   5.18 (-6.16%)
MU   69.33 (+0.62%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.11 (+2.63%)
AMC   11.67 (-2.99%)
PFE   53.11 (+1.22%)
PYPL   81.04 (+0.62%)
NFLX   185.30 (-0.56%)
S&P 500   3,974.66 (+1.88%)
DOW   31,905.05 (+2.06%)
QQQ   292.50 (+1.32%)
AAPL   142.57 (+3.62%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,228.67 (+2.32%)
AMZN   2,145.31 (-0.30%)
TSLA   673.31 (+1.42%)
NVDA   167.74 (+0.48%)
BABA   86.51 (-0.32%)
NIO   15.78 (-4.01%)
AMD   94.68 (+1.26%)
CGC   5.18 (-6.16%)
MU   69.33 (+0.62%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.11 (+2.63%)
AMC   11.67 (-2.99%)
PFE   53.11 (+1.22%)
PYPL   81.04 (+0.62%)
NFLX   185.30 (-0.56%)
S&P 500   3,974.66 (+1.88%)
DOW   31,905.05 (+2.06%)
QQQ   292.50 (+1.32%)
AAPL   142.57 (+3.62%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,228.67 (+2.32%)
AMZN   2,145.31 (-0.30%)
TSLA   673.31 (+1.42%)
NVDA   167.74 (+0.48%)
BABA   86.51 (-0.32%)
NIO   15.78 (-4.01%)
AMD   94.68 (+1.26%)
CGC   5.18 (-6.16%)
MU   69.33 (+0.62%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.11 (+2.63%)
AMC   11.67 (-2.99%)
PFE   53.11 (+1.22%)
PYPL   81.04 (+0.62%)
NFLX   185.30 (-0.56%)
NASDAQ:AMRN

Amarin (AMRN) Stock Forecast, Price & News

$1.44
+0.02 (+1.06%)
(As of 05/23/2022 02:17 PM ET)
Add
Compare
Today's Range
$1.41
$1.47
50-Day Range
$1.13
$3.69
52-Week Range
$1.11
$5.97
Volume
62,331 shs
Average Volume
4.08 million shs
Market Capitalization
$569.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.08
30 days | 90 days | 365 days | Advanced Chart
Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

Amarin logo

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Headlines

HC Wainwright Lowers Amarin (NASDAQ:AMRN) to Neutral
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMRN
Fax
N/A
Employees
560
Year Founded
1991

Sales & Book Value

Annual Sales
$583.19 million
Cash Flow
$0.06 per share
Book Value
$1.62 per share

Profitability

Net Income
$7.73 million
Pretax Margin
-3.00%

Debt

Price-To-Earnings

Miscellaneous

Free Float
385,953,000
Market Cap
$569.04 million
Optionable
Optionable

Company Calendar

Last Earnings
5/04/2022
Today
5/23/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.05 out of 5 stars

Medical Sector

527th out of 1,416 stocks

Pharmaceutical Preparations Industry

236th out of 677 stocks

Analyst Opinion: 4.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -













Amarin (NASDAQ:AMRN) Frequently Asked Questions

Is Amarin a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Amarin stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRN, but not buy additional shares or sell existing shares.
View analyst ratings for Amarin
or view top-rated stocks.

When is Amarin's next earnings date?

Amarin is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Amarin
.

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) posted its earnings results on Wednesday, May, 4th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.06. The biopharmaceutical company earned $94.60 million during the quarter, compared to the consensus estimate of $128.21 million. Amarin had a negative trailing twelve-month return on equity of 1.31% and a negative net margin of 4.15%. The company's revenue for the quarter was down 33.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.03 earnings per share.
View Amarin's earnings history
.

What price target have analysts set for AMRN?

5 Wall Street analysts have issued twelve-month target prices for Amarin's stock. Their forecasts range from $3.00 to $10.00. On average, they anticipate Amarin's stock price to reach $5.33 in the next twelve months. This suggests a possible upside of 271.7% from the stock's current price.
View analysts' price targets for Amarin
or view top-rated stocks among Wall Street analysts.

Who are Amarin's key executives?
Amarin's management team includes the following people:
  • Mr. Michael W. Kalb, CFO, Sr. VP & Assistant Sec. (Age 51, Pay $656.66k) (LinkedIn Profile)
  • Dr. Steven B. Ketchum Ph.D., Pres of R&D, Exec. VP and Chief Scientific Officer (Age 57, Pay $758.14k)
  • Mr. Aaron D. Berg, Exec. VP & Pres of U.S. (Age 59, Pay $656.09k)
  • Mr. Karim Mikhail, Pres, CEO & Director (Age 51)
  • Ms. Lisa M. DeFrancesco, Sr. VP of Corp. Affairs & Investor Relations (Age 42)
  • Mr. Jason M. Marks J.D., Exec. VP, Chief Legal and Compliance Officer & Corp. Sec. (Age 46)
  • Alina Kolomeyer, Director of Communications
  • Mr. Alan J. Wills B.A., BA (Zoology), M.B.A., MBA, Exec. VP of Corp. Bus. Devel. (Age 59)
  • Ms. Donna Pasek, Sr. VP of HR
  • Dr. Keith Wood, Head of R&D Operations
What is John Thero's approval rating as Amarin's CEO?

10 employees have rated Amarin CEO John Thero on Glassdoor.com. John Thero has an approval rating of 93% among Amarin's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), (CGC), Square (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

Who are Amarin's major shareholders?

Amarin's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sarissa Capital Management LP (6.05%), Eversept Partners LP (2.26%), Clearbridge Investments LLC (1.21%), Fairmount Funds Management LLC (1.04%), Kynam Capital Management LP (0.58%) and 13D Management LLC (0.51%). Company insiders that own Amarin stock include David M Stack, John F Thero, Joseph S Zakrzewski, Michael Wayne Kalb and Steven B Ketchum.
View institutional ownership trends for Amarin
.

Which major investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including Eversept Partners LP, Group One Trading L.P., Jane Street Group LLC, Edgestream Partners L.P., IMC Chicago LLC, Evanson Asset Management LLC, Williams Jones Wealth Management LLC., and Handelsbanken Fonder AB.
View insider buying and selling activity for Amarin
or view top insider-selling stocks.

Which major investors are buying Amarin stock?

AMRN stock was acquired by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, 13D Management LLC, Fairmount Funds Management LLC, Goldman Sachs Group Inc., Kynam Capital Management LP, Commonwealth Equity Services LLC, LCM Capital Management Inc, and Cutter & CO Brokerage Inc.. Company insiders that have bought Amarin stock in the last two years include David M Stack, and Joseph S Zakrzewski.
View insider buying and selling activity for Amarin
or or view top insider-buying stocks.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $1.44.

How much money does Amarin make?

Amarin has a market capitalization of $569.04 million and generates $583.19 million in revenue each year. The biopharmaceutical company earns $7.73 million in net income (profit) each year or ($0.050010) on an earnings per share basis.

How many employees does Amarin have?

Amarin employs 560 workers across the globe.

Does Amarin have any subsidiaries?

The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.

When was Amarin founded?

Amarin was founded in 1991.

What is Amarin's official website?

The official website for Amarin is www.amarincorp.com.

How can I contact Amarin?

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at (531) 669-9020 or via email at [email protected].

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.